Prophylaxis to prevent infective endocarditis: to use or not to use?
The American Heart Association (AHA) published their revised guidelines in 2007 in which they markedly limited the recommendations for the use of antimicrobial prophylaxis for the prevention of infective endocarditis (IE), except for patients who are at highest risk of adverse outcomes. A recent focused update on valvular heart diseases changed the recommendation for antibiotic use for patients with many underlying heart conditions including mitral valve prolapse (MVP) which were considered as "low risk" heart defects. In this article, we argue that antibiotic prophylaxis should be considered until concrete clinical evidence is provided to dispute against the use of this strategy, especially for patients with MVP. This approach is cost efficient, and provides a chance to prevent a dreadful disease. We have also enlisted 2 clinical cases to support our argument. These are not uncommon clinical scenarios, and emphasize that IE can be fatal in spite of optimum treatment. Patients have the right to make the final decision, and they should be allowed to participate in choosing for or against this approach until adequate clinical evidence is available.
Dhoble
Abhijeet
A
Department of Internal Medicine, Michigan State University, East Lansing, Michigan 48824-1313, USA. Abhijeet.Dhoble@ht.msu.edu
Vedre
Ameeth
A
Abdelmoneim
Sahar S
SS
Sudini
Srikar Reddy
SR
Ghose
Amit
A
Abela
George S
GS
Karve
Milind
M
D000572:American Heart Association; D019072:Antibiotic Prophylaxis / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017548:Echocardiography, Transesophageal; D004696:Endocarditis / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D017809:Fatal Outcome; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D008945:Mitral Valve Prolapse / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010353:Patient Education as Topic; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D014081:Tooth Extraction / Q000009:adverse effects*; D016896:Treatment Outcome; D014481:United States
J Am Coll Cardiol. 2008 Aug 5;52(6):495-7
18672172
Eur Heart J. 2004 Feb;25(3):267-76
14972429
Am J Cardiol. 1987 Jan 1;59(1):105-8
3812219
J Antimicrob Chemother. 2006 Jun;57(6):1035-42
16624872
Cochrane Database Syst Rev. 2004;(2):CD003813
15106220
JAMA. 1997 Jun 11;277(22):1794-801
9178793
Am J Cardiol. 1994 Nov 15;74(10):1024-9
7977041
Am J Cardiol. 1994 Feb 1;73(4):263-7
8296757
J Am Coll Cardiol. 2008 Aug 19;52(8):676-85
18702976
Arq Bras Cardiol. 1990 Feb;54(2):101-4
2260932
Emerg Infect Dis. 2004 Jun;10(6):1110-6
15207065
BMJ. 2008 Apr 5;336(7647):770-1
18390528
Circulation. 2007 Oct 9;116(15):1736-54
17446442
Pediatr Cardiol. 1999 Sep-Oct;20(5):317-25
10441684
Clin Genet. 2007 Oct;72(4):288-95
17850623
Aust Dent J. 2008 Sep;53(3):196-200; quiz 297
18782362